Pharmaceutical News

RSS

Existing drug could be repurposed to treat type 1 diabetes, study suggests

Type 1 diabetes is an autoimmune disease that causes the body's immune system to attack and destroy insulin-producing beta cells in the pancreas. Traditional management of type 1 diabetes has primarily involved replacing the missing insulin with injections which, though effective, can be expensive and burdensome.

1 Nov 2023

Repurposing of DFMO could lead to innovative therapies for type 1 diabetes

A recent study led by Indiana University School of Medicine in collaboration with the University of Chicago Medicine presents exciting future possibilities for the management of type 1 diabetes and the potential reduction of insulin dependency.

1 Nov 2023

JAK inhibitors offer effective and convenient treatment option for arthritis patients

According to a new paper in Rheumatology, published by Oxford University Press, JAK inhibitors, which doctors have used to treat patients with arthritis despite concerns about the effectiveness of such drugs, actually do work quite well.

1 Nov 2023

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns

In a recent study published in Nature Communications, researchers developed a scoring mechanism based on artificial intelligence for early drug discovery campaigns that might be utilized for compound prioritizing, motif rationalization, and biased drug design.

1 Nov 2023

How next-gen sequencing is changing antibody drug discovery

New study outlines how next-generation sequencing (NGS) and machine-learning methods can revolutionize antibody discovery, particularly against SARS-CoV-2. The research demonstrates that NGS provides greater epitopic and paratopic diversity, enabling more effective identification and prioritization of therapeutic antibodies.

31 Oct 2023

Trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer

The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also be used as monotherapy for the treatment of adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy at this disease stage or developed disease recurrence early after adjuvant chemotherapy.

31 Oct 2023

New AI tool could lead to precision medicine by predicting drug response

An ideal medicine for one person may prove ineffective or harmful for someone else, and predicting who could benefit from a given drug has been difficult.

31 Oct 2023

New drug gets FDA approval for the treatment of common genetic disease in young boys

A new drug developed by professors from the School of Pharmacy and Pharmaceutical Sciences at Binghamton University has received Food and Drug Administration (FDA) approval for the treatment of patients with Duchenne muscular dystrophy (DMD), a common genetic disease that mostly affects young boys.

31 Oct 2023

Antibiotics no longer effective in treating childhood infections in large parts of the world

Drugs to treat common infections in children and babies are no longer effective in large parts of the world, due to high rates of antibiotic resistance.

31 Oct 2023

Day-to-day painkiller use doesn't lower empathy levels, but misuse might, according to recent survey

The association between low empathy and prosocial behavior on the one hand and analgesic consumption.

30 Oct 2023

Stopping metformin early linked to higher dementia risk in older adults with type 2 diabetes

Early termination of metformin treatment in older adults with type 2 diabetes is associated with a higher risk of dementia, according to a cohort study. The research has significant implications for diabetes management, especially among those at higher risk for dementia.

29 Oct 2023

New study highlights risks of anti-ERBB2 cancer drugs during pregnancy

Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine growth restriction. Researchers recommend careful monitoring and possibly discontinuing these drugs during pregnancy despite their effectiveness against cancer.

29 Oct 2023

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

28 Oct 2023

Low-cost anti-inflammatory hydrogel could help treat chronic skin lesions in people with diabetes

Researchers in São Paulo state, Brazil, have developed a low-cost anti-inflammatory hydrogel that in future could help treat chronic skin lesions such as those often seen in people with diabetes.

27 Oct 2023

FDA approves a new steroidal-type anti-inflammatory drug for Duchenne muscular dystrophy

Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration's approval Thursday of vamorolone, a steroidal-type, anti-inflammatory drug developed based on research performed at Children's National Hospital.

27 Oct 2023

AI-designed drug candidate shows promise for gastric acid inhibition

Researchers at Nagoya University in Japan created and improved artificial intelligence (AI) designs to synthesize a candidate compound for a new gastric acid inhibitor with a better binding affinity than existing drugs.

26 Oct 2023

Study finds link between industry payments to oncologists and non-recommended cancer treatments

Patients with cancer whose oncologist receives payments from industry appear more likely to receive some non-recommended and low value treatments, finds a US study published by The BMJ today.

25 Oct 2023

NF-κB activation during COVID-19 and its impact on patients with hypertension

Researchers review the role of NF-κB activation in the replication of SARS-CoV-2 and the impact of COVID-19 medications on NF-κB activation.

25 Oct 2023

Scientists achieve breakthrough in treating 'neglected' polymyalgia rheumatica

Scientists have found success in treating a 'neglected' inflammatory condition, polymyalgia rheumatica, with a drug that could provide an alternative to steroids for patients.

25 Oct 2023

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

Like several immunosuppressive biologics, the JAK inhibitor upadacitinib is also approved for the treatment of Crohn's disease. Commissioned by the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated in an early benefit assessment whether the drug offers an added benefit versus the appropriate comparator therapy to patients with moderate to severe active Crohn's disease who have had an inadequate response, lost response or are intolerant to conventional therapy or a biologic agent.

25 Oct 2023

Previous
1
...
43
44
45
46
47
48
49
...
1443
Next

Pharmaceutical News

Existing drug could be repurposed to treat type 1 diabetes, study suggests

Repurposing of DFMO could lead to innovative therapies for type 1 diabetes

JAK inhibitors offer effective and convenient treatment option for arthritis patients

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns

How next-gen sequencing is changing antibody drug discovery

Trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer

New AI tool could lead to precision medicine by predicting drug response

New drug gets FDA approval for the treatment of common genetic disease in young boys

Antibiotics no longer effective in treating childhood infections in large parts of the world

Day-to-day painkiller use doesn't lower empathy levels, but misuse might, according to recent survey

Stopping metformin early linked to higher dementia risk in older adults with type 2 diabetes

New study highlights risks of anti-ERBB2 cancer drugs during pregnancy

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

Low-cost anti-inflammatory hydrogel could help treat chronic skin lesions in people with diabetes

FDA approves a new steroidal-type anti-inflammatory drug for Duchenne muscular dystrophy

AI-designed drug candidate shows promise for gastric acid inhibition

Study finds link between industry payments to oncologists and non-recommended cancer treatments

NF-κB activation during COVID-19 and its impact on patients with hypertension

Scientists achieve breakthrough in treating 'neglected' polymyalgia rheumatica

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News